Lyell Immunopharma Inc

Lyell Immunopharma CFO Shah Smital exercises 140 k zero‑cost options, boosting insider confidence and aligning exec incentives with the company’s high‑growth biotech future.

Lyell Immunopharma insiders sell shares for tax liquidity, not confidence drops, while the stock remains 12% above its 52‑week low after a CAR‑T rally.

Lyell Immunopharma’s insider buying spree signals executive confidence amid high volatility—what this means for investors and the company’s next steps.